Trials / Completed
CompletedNCT01558323
Pharmacokinetics of LCQ908 in Patients With Renal Impairment
An Open-label, Parallel-group, Single Dose Study to Assess the Pharmacokinetics of LCQ908 in Patients With Mild, Moderate and Severe Renal Impairment Compared to Age, Gender and Weight-matched Healthy Volunteers.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This study will compare the pharmacokinetics of LCQ908 in subjects with varying degrees of renal impairment to healthy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LCQ908 | Participants will receive a single oral dose of LCQ908 |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2013-03-01
- Completion
- 2013-03-01
- First posted
- 2012-03-20
- Last updated
- 2020-12-19
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01558323. Inclusion in this directory is not an endorsement.